Cutaneous Melanoma

Great collaboration with @YanaNajjarMD @UPMCHillmanCC on this paper led by superstar trainee @RyanAugustinMD! Metformin use is associated with decreased recurrence rates for early stage cutaneous melanoma. Now it’s time for us to dig into potential mechanisms! (@DrBetofMDPhD)

ALK Mutation is present in 2.81% of @AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence. https://t.co/xqPTiPcovZ @ALKPositiveinc… https://t.co/KcF0yqWyPP (@4baseCare)

Staging should not include histology nor LVSI. That is not what staging should be about! Guess we will do a new cutaneous melanoma staging and use mucosal as a criteria for stage. This is very misguided (@leitaomd)

New #JITC article: Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study https://t.co/HGnmbOlaQa @OmidHamidMD @jmkirkwood @PAscierto (@jitcancer)

🎥@jasonlukemd of @PittTweet presents key insights from the Phase III KEYNOTE-716 trial at #ASCO23. Exciting results show pembrolizumab's efficacy in high-risk cutaneous melanoma, redefining treatment options in the adjuvant setting: ➡️https://t.co/0oc2n9MVk4⬅️ #MelSM #SkcSM (@VJOncology)

I am so sorry to hear this. I lost my husband to (cutaneous) Melanoma just before we had the new drugs- it is heart-breaking to be so powerless in the face of a disease. You both are in my thoughts ♥️ (@BettinaRyll)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHrLyF #melsm #PrecisionMedicine (@mtmdphd)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHsjod #melsm #PrecisionMedicine (@mtmdphd)

Results from our randomized phase 2 trial clearly demonstrate the benefit of neoadjuvant PD-1 for advanced cutaneous melanoma. Proud to be a part of the melanoma team @SWOG and looking forward to more exciting progress in this field! ⁦⁦@uscnorris⁩ https://t.co/VB5WML4Vob (@Gino_K_In_USC)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHJmqd #melsm #PrecisionMedicine cc @MDAndersonNews (@mtmdphd)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHrLyF #melsm #PrecisionMedicine cc @MDAndersonNews (@mtmdphd)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHsjod #melsm #PrecisionMedicine cc @MDAndersonNews (@mtmdphd)

Proffered paper session - Investigational Immunotherapy: Promising results of the phase 1 study assessing IMC-F106C - ImmTAC targeting PRAME/CD3 solid tumors presented by Dr @OmidHamidMD Interesting data, especially in pretreated cutaneous melanoma and Tebe-naïve uveal pts. (@mauriciofribei1)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHrLyF #melsm #PrecisionMedicine (@mtmdphd)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF… [Feb 28, 2014] Mike Davies, MD, PhD in @JPCRR https://t.co/LUszZHrLyF #melsm #PrecisionMedicine cc @MDAndersonNews (@mtmdphd)

Congratulations to the group for this terrific multicentre effort..clearly not the same outcomes with PD1× as in cutaneous melanoma.. Need to study the addition of TKI to IO for this orphan disease in a prospective trial.. (@todrashish)

MET Amplification is seen in LUAD, GBM, colon adenocarcinoma, esophageal adenocarcinoma, and cutaneous melanoma. Two among numerous trials: Volitinib in Recurrent or Refractory Primary CNS Tumors (NCT03598244), Savolitinib in CRC (NCT03592641). (@anu_iris)

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma https://t.co/vvyDKQSUxm (@NewsFromBW)